Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Iamgold Corporation Ordinary Shares (IAG) vs TG Therapeutics Inc (TGTX) Price & Performance

Iamgold Corporation Ordinary SharesTrade
TG Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Iamgold Corporation Ordinary Shares vs TG Therapeutics Inc — how do they compare? Iamgold Corporation Ordinary Shares trades at $18.85 (market cap $10.49B), while TG Therapeutics Inc trades at $54.84 (market cap $8.16B). The key difference: Iamgold Corporation Ordinary Shares is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Iamgold Corporation Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iamgold Corporation Ordinary Shares for 1 Days and TG Therapeutics Inc for 16 Days on average.

IAGTGTX
Market Cap
$10.49B$8.16B
Volume
3,160,9021,735,121
Sector
Basic MaterialsHealth
52-Week High
$24.57$59.06
52-Week Low
$10.96$26.94
Typical Hold Time
1 Days16 Days
Enterprise Value
$10.53B$8.37B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Iamgold Corporation Ordinary Shares

No Aura AI signal available yet.

TG Therapeutics Inc

TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.

The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IAG

No sentiment data available yet.

TGTX
0% Buy100% Sell
Avg holding period · 16 Days

About Iamgold Corporation Ordinary Shares

IAMGOLD is a gold mining company with operations in Canada. It also explores and develops gold properties.

Read more on IAG →

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Read more on TGTX →